155 related articles for article (PubMed ID: 19209238)
1. Comparative mitochondrial proteomic analysis of Rji cells exposed to adriamycin.
Jiang YJ; Sun Q; Fang XS; Wang X
Mol Med; 2009; 15(5-6):173-82. PubMed ID: 19209238
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial proteomics with siRNA knockdown to reveal ACAT1 and MDH2 in the development of doxorubicin-resistant uterine cancer.
Lo YW; Lin ST; Chang SJ; Chan CH; Lyu KW; Chang JF; May EW; Lin DY; Chou HC; Chan HL
J Cell Mol Med; 2015 Apr; 19(4):744-59. PubMed ID: 25639359
[TBL] [Abstract][Full Text] [Related]
3. Comparative mitochondrial proteomic analysis of hepatocellular carcinoma from patients.
Ye Y; Huang A; Huang C; Liu J; Wang B; Lin K; Chen Q; Zeng Y; Chen H; Tao X; Wei G; Wu Y
Proteomics Clin Appl; 2013 Jun; 7(5-6):403-15. PubMed ID: 23589362
[TBL] [Abstract][Full Text] [Related]
4. Quantitative proteomics analysis identifies mitochondria as therapeutic targets of multidrug-resistance in ovarian cancer.
Chen X; Wei S; Ma Y; Lu J; Niu G; Xue Y; Chen X; Yang F
Theranostics; 2014; 4(12):1164-75. PubMed ID: 25285166
[TBL] [Abstract][Full Text] [Related]
5. Identification of proteins responsible for the development of adriamycin resistance in human gastric cancer cells using comparative proteomics analysis.
Yang YX; Hu HD; Zhang DZ; Ren H
J Biochem Mol Biol; 2007 Nov; 40(6):853-60. PubMed ID: 18047778
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of mitochondria in Raji cells following exposure to radiation: implications for radiotherapy response.
Jiang Y; Liu X; Fang X; Wang X
Protein Pept Lett; 2009; 16(11):1350-9. PubMed ID: 20001925
[TBL] [Abstract][Full Text] [Related]
7. Nuclear proteomics with XRCC3 knockdown to reveal the development of doxorubicin-resistant uterine cancer.
Chang JF; Lin ST; Hung E; Lu YL; Soon May EW; Lo YW; Chou HC; Chan HL
Toxicol Sci; 2014 Jun; 139(2):396-406. PubMed ID: 24675091
[TBL] [Abstract][Full Text] [Related]
8. Alterations in the mitochondrial proteome of adriamycin resistant MCF-7 breast cancer cells.
Strong R; Nakanishi T; Ross D; Fenselau C
J Proteome Res; 2006 Sep; 5(9):2389-95. PubMed ID: 16944951
[TBL] [Abstract][Full Text] [Related]
9. Redox proteomic identification of oxidized cardiac proteins in adriamycin-treated mice.
Chen Y; Daosukho C; Opii WO; Turner DM; Pierce WM; Klein JB; Vore M; Butterfield DA; St Clair DK
Free Radic Biol Med; 2006 Nov; 41(9):1470-7. PubMed ID: 17023274
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
[TBL] [Abstract][Full Text] [Related]
11. A proteomic investigation into adriamycin chemo-resistance of human leukemia K562 cells.
Peng X; Gong F; Xie G; Zhao Y; Tang M; Yu L; Tong A
Mol Cell Biochem; 2011 May; 351(1-2):233-41. PubMed ID: 21243406
[TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line.
Keenan J; Murphy L; Henry M; Meleady P; Clynes M
Proteomics; 2009 Mar; 9(6):1556-66. PubMed ID: 19242932
[TBL] [Abstract][Full Text] [Related]
13. Peiminine serves as an adriamycin chemosensitizer in gastric cancer by modulating the EGFR/FAK pathway.
Tang Q; Wang Y; Ma L; Ding M; Li T; Nie Y; Gu Z
Oncol Rep; 2018 Mar; 39(3):1299-1305. PubMed ID: 29328433
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.
Feng R; Dong L
Int J Clin Exp Pathol; 2015; 8(6):6107-16. PubMed ID: 26261488
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance.
Li RJ; Zhang GS; Chen YH; Zhu JF; Lu QJ; Gong FJ; Kuang WY
Ann Oncol; 2010 Jul; 21(7):1506-1514. PubMed ID: 20038517
[TBL] [Abstract][Full Text] [Related]
16. Involvement of annexin A1 in multidrug resistance of K562/ADR cells identified by the proteomic study.
Zhu F; Wang Y; Zeng S; Fu X; Wang L; Cao J
OMICS; 2009 Dec; 13(6):467-76. PubMed ID: 20001861
[TBL] [Abstract][Full Text] [Related]
17. Identification of up- and down-regulated proteins in doxorubicin-resistant uterine cancer cells: reticulocalbin-1 plays a key role in the development of doxorubicin-associated resistance.
May EW; Lin ST; Lin CC; Chang JF; Hung E; Lo YW; Lin LH; Hu RY; Feng CL; Lin DY; Wu SB; Lee WC; Lyu KW; Chou HC; Chan HL
Pharmacol Res; 2014 Dec; 90():1-17. PubMed ID: 25242635
[TBL] [Abstract][Full Text] [Related]
18. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
[TBL] [Abstract][Full Text] [Related]
19. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis.
Chen J; Wang W; Wang H; Liu X; Guo X
Drug Discov Ther; 2014 Feb; 8(1):33-41. PubMed ID: 24647156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
